Finance

Lists
TRAX:NASDAQ
First Tracks Biotherapeutics Inc
$42.86
-5.80%
(-2.64) 1D
Aug 20, 12:12:50 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRAX...
Open
$45.50
High
$45.99
Low
$42.47
Mkt. cap
1.53B
Avg. vol.
908.28K
Volume
117.49K
52-wk high
$49.91
52-wk low
$14.88
Shares outstanding
35.73M
No. of employees
104
Open
$45.50
High
$45.99
Low
$42.47
Mkt. cap
1.53B
Avg. vol.
908.28K
Volume
117.49K
52-wk high
$49.91
52-wk low
$14.88
Shares outstanding
35.73M
No. of employees
104
News stories
From web sources and news partners
About First Tracks Biotherapeutics Inc
CEO-
Employees104
Founded2019
Headquarters-
SectorBiotechnology
Websitefirsttracksbio.com
Analyst ratings
Based on 7 analysts giving stock ratings to TRAX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for TRAX in the last 3 months.
Highest
Current $42.86
$95.00 (+121.65%)
Average
$66.00 (+53.99%)
Lowest
$55.00 (+28.32%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$95.00
+121.7%
08/20/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$65.00
+51.7%
08/19/2026
Michael Yee
UBS
Buy
Reiterated
$65.00
+51.7%
08/13/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$57.00
+33%
08/13/2026
Etzer Darout
Barclays
Buy
Maintained
$65.00
+51.7%
08/12/2026
Martin Fan
Wedbush
Buy
Maintained
$60.00
+40%
07/28/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$55.00
+28.3%
07/28/2026
Unknown Analyst
UBS
Buy
Maintained
$45.00
+5%
07/10/2026
David Risinger
Leerink Partners
Buy
Initiated
$46.00
+7.3%
04/24/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.95 / -$0.81
-17.27%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
41.46M
39.27M
33.96M
25.64M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.82M
6.63M
18.86M
9.29M
Operating expense
51.28M
45.90M
52.81M
34.94M
Total operating expenses
51.28M
45.90M
52.81M
34.94M
Operating income
-51.28M
-45.90M
-52.81M
-34.94M
Other non operating income
-7.00K
-13.00K
-1.00K
-1.00K
EBT including unusual items
-47.20M
-42.44M
-50.48M
-33.37M
EBT excluding unusual items
-47.20M
-42.44M
-50.48M
-33.37M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-47.20M
-42.44M
-50.48M
-33.37M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-0.95
Interest and investment income
4.09M
3.47M
2.33M
1.56M
Interest expense
-
-
-
-
Net interest expenses
4.09M
3.47M
2.33M
1.56M
Depreciation and amortization charges
-
-
-
-
EBITDA
-51.13M
-45.76M
-52.69M
-34.83M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps